These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Therapy for cystic fibrosis--the end of the beginning? Davis PB N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565 [No Abstract] [Full Text] [Related]
26. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment. Hull J J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S2-8. PubMed ID: 22688363 [No Abstract] [Full Text] [Related]
27. Lung clearance index response in patients with CF with class III CFTR mutations. Kane M; Gonska T; Jensen R; Avolio J; Klingel M; Stanojevic S; Ratjen F Thorax; 2016 May; 71(5):476-7. PubMed ID: 26944510 [No Abstract] [Full Text] [Related]
28. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Jones AM; Barry PJ Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414 [No Abstract] [Full Text] [Related]
31. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
32. Highlights of the North American Cystic Fibrosis Conference 2011. Pabary R; Thursfield R; Davies JC J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S9-13. PubMed ID: 22688370 [No Abstract] [Full Text] [Related]
33. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy. Hayes D; Long FR; McCoy KS; Sheikh SI Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273 [No Abstract] [Full Text] [Related]
34. Mutation-specific cystic fibrosis treatments on verge of approval. Dolgin E Nat Med; 2011 Apr; 17(4):396-7. PubMed ID: 21475213 [No Abstract] [Full Text] [Related]
35. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688 [No Abstract] [Full Text] [Related]
36. Update in Cystic Fibrosis 2014. Ong T; Ramsey BW Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812 [No Abstract] [Full Text] [Related]
37. Update in cystic fibrosis 2013. Jain M; Goss CH Am J Respir Crit Care Med; 2014 May; 189(10):1181-6. PubMed ID: 24832742 [No Abstract] [Full Text] [Related]
38. PharmGKB summary: very important pharmacogene information for CFTR. McDonagh EM; Clancy JP; Altman RB; Klein TE Pharmacogenet Genomics; 2015 Mar; 25(3):149-56. PubMed ID: 25514096 [No Abstract] [Full Text] [Related]
39. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. Ramsey BW; Welsh MJ Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323 [No Abstract] [Full Text] [Related]
40. Modifying disease in cystic fibrosis: current and future therapies on the horizon. Ong T; Ramsey BW Curr Opin Pulm Med; 2013 Nov; 19(6):645-51. PubMed ID: 24048086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]